Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 30 January 2026 - 1 February 2026

Novo Nordisk stock heads into earnings week as Wegovy pill scripts top 26,000

Novo Nordisk stock heads into earnings week as Wegovy pill scripts top 26,000

Novo Nordisk Class B shares closed at 369.6 Danish crowns on Friday, down 0.8 crown, as investors awaited the company’s 2025 financial statement set for Feb. 4. U.S. prescriptions for the new Wegovy pill surged to 26,109 in the week ending Jan. 23, up sharply from its launch. Leadership changes in China and rising competition from AstraZeneca add pressure ahead of earnings.
1 February 2026
···
AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca shares closed in London at 135.48 pounds Friday, up 0.65%. The company moves its U.S. listing from Nasdaq to the NYSE on Monday, keeping the AZN ticker. AstraZeneca recently announced a $1.2 billion obesity drug deal with CSPC and pledged $15 billion investment in China by 2030. Investors await full-year results on Feb. 10.
1 February 2026
···
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B stock price: Wegovy pill scripts hit 26,000 as earnings week approaches

Novo Nordisk Class B shares closed down 0.23% at 369.55 Danish kroner Friday, capping a 7.9% slide over five sessions. U.S. prescriptions for oral Wegovy reached 26,109 in the week ending Jan. 23, after 3,071 in the first four days post-launch. The company faces rising competition in China and awaits EU approval for its MASH drug. Quarterly results and 2026 outlook are due Feb. 4.
31 January 2026
···
AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

AstraZeneca agreed to license obesity drug candidates from CSPC Pharmaceutical in a deal worth up to $18.5 billion, paying $1.2 billion upfront. AstraZeneca shares rose 0.65% in London, while CSPC shares fell nearly 12% in Hong Kong. The deal gives AstraZeneca rights outside Greater China and includes a once-monthly GLP-1/GIP agonist entering Phase I trials. AstraZeneca will also delist its ADS from Nasdaq and move to the NYSE.
31 January 2026
··
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
······
AbbVie stock (ABBV) firms up into earnings week as markets turn cautious

AbbVie stock (ABBV) firms up into earnings week as markets turn cautious

AbbVie shares rose 1.17% to $223.01 Friday, outperforming a broader market dip after Donald Trump nominated Kevin Warsh to lead the Federal Reserve. Trading volume in AbbVie topped its 50-day average ahead of next week’s earnings report. The stock remains about 9% below its 52-week high. AbbVie will release results and hold its earnings call early Wednesday.
31 January 2026
···
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly shares rose 1.3% to $1,037.15 after announcing a $3.5 billion injectable drug plant in Pennsylvania, set to create 850 permanent jobs by 2031. The plant will produce next-generation weight-loss drugs, including retatrutide. The European regulator declined a new use for Mounjaro in heart failure but will update prescribing info. Lilly’s Q4 results are due Feb. 4.
31 January 2026
···
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly shares rose 1.3% to $1,037.15 in after-hours trading Friday after announcing a $3.5 billion facility in Fogelsville, Pennsylvania to produce injectable weight-loss drugs, including retatrutide. Pennsylvania will contribute $100 million to the project, which is expected to create 850 permanent jobs and start operations by 2031.
31 January 2026
···
Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck shares rose 1.2% to $109.64 Friday afternoon, outperforming a falling S&P 500. Health care stocks attracted buyers as inflation data came in hotter than expected and Donald Trump named Kevin Warsh as Federal Reserve chair. Investors are watching for Merck’s Feb. 3 earnings call, with focus on 2026 guidance and Keytruda sales trends.
30 January 2026
···
AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie stock rises as ABBV heads into Feb. 4 earnings; Botox price talks in focus

AbbVie shares rose about 1% Friday, closing near $222.73 ahead of its Feb. 4 earnings report and first 2026 guidance. Investors are watching Botox pricing risks after Medicare listed it for price negotiations, and new aesthetics data from Paris. The stock dropped 2.35% Wednesday, ending a five-day rally. Goldman Sachs kept a neutral rating with a $223 target.
30 January 2026
···
1 2 3 4 5 6 … 34

Stock Market Today

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

7 February 2026
Toyota shares rose 2% to 3,780 yen Friday after the company raised its full-year profit forecast and announced CFO Kenta Kon will replace CEO Koji Sato on April 1. Third-quarter net revenues climbed 6.8% to 38.087 trillion yen, but North America posted a 5.6 billion yen operating loss. Toyota’s U.S. ADRs closed up 2.9%. The tender offer for Toyota Industries shares closes Feb. 12.
HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

7 February 2026
HSBC shares closed up 2.2% at £13.06 on Friday, reversing Thursday’s drop as traders weighed possible Bank of England rate cuts and awaited the bank’s annual results on Feb. 25. The FTSE 100 rose 0.6%, with major UK banks also gaining. HSBC is also preparing to cut some banker bonuses and push out underperformers amid a cost reset. Key UK, U.S., and euro zone economic data are due next week.
Go toTop